129 related articles for article (PubMed ID: 27541072)
1. Adverse effects of imatinib in children with chronic myelogenous leukemia.
Choeyprasert W; Yansomdet T; Natesirinilkul R; Wejaphikul K; Charoenkwan P
Pediatr Int; 2017 Mar; 59(3):286-292. PubMed ID: 27541072
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
Cai Y; Liu C; Guo Y; Chen X; Zhang L; Chen Y; Zou Y; Yang W; Zhu X
Int J Hematol; 2021 Mar; 113(3):413-421. PubMed ID: 33386594
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
Rastogi MV; Stork L; Druker B; Blasdel C; Nguyen T; Boston BA
Pediatr Blood Cancer; 2012 Nov; 59(5):840-5. PubMed ID: 22378641
[TBL] [Abstract][Full Text] [Related]
4. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.
Narayanan KR; Bansal D; Walia R; Sachdeva N; Bhansali A; Varma N; Marwaha RK
Pediatr Blood Cancer; 2013 Jul; 60(7):1148-53. PubMed ID: 23322583
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China.
Deng M; Guan X; Wen X; Xiao J; An X; Yu J
Medicine (Baltimore); 2020 Feb; 99(7):e19150. PubMed ID: 32049841
[TBL] [Abstract][Full Text] [Related]
8. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
9. First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia.
Capron A; Antunes MV; Wagner SC; Mattevi VS; Vieira N; Leite R; Reginato F; Capra M; Fogliatto L; Wallemacq P; Linden R
Clin Chim Acta; 2016 Jan; 453():42-7. PubMed ID: 26657979
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
11. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.
Millot F; Guilhot J; Nelken B; Leblanc T; De Bont ES; Békassy AN; Gadner H; Sufliarska S; Stary J; Gschaidmeier H; Guilhot F; Suttorp M
Leukemia; 2006 Feb; 20(2):187-92. PubMed ID: 16341042
[TBL] [Abstract][Full Text] [Related]
14. Long term outcome of chronic myeloid leukemia patients treated with imatinib: Report from a developing country.
Absar M; Akhtar T; Jameel A; Mahmood A; Ullah A; Aleem A; Qureshi K; Rehman N; Iqbal Z
Pak J Pharm Sci; 2020 Mar; 33(2(Supplementary)):861-870. PubMed ID: 32863263
[TBL] [Abstract][Full Text] [Related]
15. Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase.
Chang X; Zhou L; Chen X; Xu B; Cheng Y; Sun S; Fang M; Xiang Y
Target Oncol; 2017 Dec; 12(6):827-832. PubMed ID: 28791527
[TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
17. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.
Ulmer A; Tabea Tauer J; Glauche I; Jung R; Suttorp M
Klin Padiatr; 2013 May; 225(3):120-6. PubMed ID: 23716272
[TBL] [Abstract][Full Text] [Related]
18. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia.
Novaković S; Kovač Peić A; Holik H; Coha B
Acta Clin Belg; 2017 Dec; 72(6):461-464. PubMed ID: 28420292
[TBL] [Abstract][Full Text] [Related]
20. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]